US Pharma MarketingASCO: Telix tees up pivotal test for Pluvicto challenger while eyeing ‘white space’ on radiopharma canvas
David Cade, the chief medical officer of Melbourne-based Telix Pharmaceuticals, traveled a long way to the American Society of Clinical Oncology meeting in Chicago with a singular goal in mind: spr David Cade, the chief medical officer of Melbourne-based Telix Pharmaceuticals, traveled a long way to the American Society of Clinical Oncology meeting in Chicago with a singular goal in mind: spread the word about Telix’s pivotal trial for a potential challenger to Novartis’ Pluvicto. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical…
David Cade, the chief medical officer of Melbourne-based Telix Pharmaceuticals, traveled a long way to the American Society of Clinical Oncology meeting in Chicago with a singular goal in mind: spread the word about Telix’s pivotal trial for a potential challenger to Novartis’ Pluvicto.
Source: FierceBiotech